EPHEDRINE SULFATE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932	ANDA	NorthStar Rx LLC	16714-037-10	10 VIAL, SINGLE-DOSE in 1 CARTON (16714-037-10) / 1 mL in 1 VIAL, SINGLE-DOSE (16714-037-01)	2020-12-02
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932	ANDA	Amneal Pharmaceuticals LLC	70121-1637-5	25 VIAL, SINGLE-DOSE in 1 CARTON (70121-1637-5) / 1 mL in 1 VIAL, SINGLE-DOSE (70121-1637-1)	2019-10-23
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932	ANDA	Amneal Pharmaceuticals LLC	70121-1637-7	10 VIAL, SINGLE-DOSE in 1 CARTON (70121-1637-7) / 1 mL in 1 VIAL, SINGLE-DOSE (70121-1637-1)	2019-10-23
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932	ANDA	Medical Purchasing Solutions, LLC	71872-7257-1	1 VIAL, SINGLE-DOSE in 1 BAG (71872-7257-1) / 1 mL in 1 VIAL, SINGLE-DOSE	2019-10-23
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932	ANDA	Medical Purchasing Solutions, LLC	71872-7269-1	1 VIAL, SINGLE-DOSE in 1 BAG (71872-7269-1) / 1 mL in 1 VIAL, SINGLE-DOSE	2019-10-23
Caplin	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	219050	ANDA	Caplin Steriles Limited	65145-158-25	25 VIAL in 1 CARTON (65145-158-25) / 1 mL in 1 VIAL (65145-158-01)	2024-08-15
Dr Reddys	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212649	ANDA	Dr. Reddy's Laboratories, Inc.	43598-725-25	25 VIAL, SINGLE-DOSE in 1 CARTON (43598-725-25) / 1 mL in 1 VIAL, SINGLE-DOSE (43598-725-11)	2021-10-04
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Ephedrine sulfate, a sympathomimetic amine, is a critical active pharmaceutical ingredient (API) used in a range of medical applications, primarily for its bronchodilator and decongestant properties. The global supply chain for ephedrine sulfate is characterized by a limited number of manufacturers, stringent regulatory oversight, and evolving market dynamics driven by therapeutic demand and potential for misuse. This analysis identifies key suppliers, examines their production capabilities, and outlines the regulatory framework governing their operations.

Who are the primary global manufacturers of Ephedrine Sulfate API?

The global production of ephedrine sulfate API is concentrated among a relatively small number of manufacturers. These entities often operate under strict Good Manufacturing Practices (GMP) and are subject to rigorous quality control and regulatory compliance. The manufacturing process typically involves either the isolation of ephedrine from natural sources like Ephedra species or synthetic routes.

Key global suppliers include:

Tianjin Jade Pharmaceutical Co., Ltd. (China): A significant producer of APIs, including ephedrine sulfate. The company is known for its large-scale production capacity and adherence to international quality standards. Its operations are overseen by Chinese regulatory authorities, and its products are often exported to various international markets.
Hubei Jialan Pharmaceutical Co., Ltd. (China): Another prominent Chinese manufacturer of ephedrine sulfate. Hubei Jialan focuses on both domestic and international supply, ensuring its manufacturing processes meet established pharmacopoeial standards.
Shandong Xinhua Pharmaceutical Co., Ltd. (China): A well-established pharmaceutical company with a broad API portfolio. Xinhua Pharmaceutical is a significant contributor to the global supply of ephedrine sulfate, with a history of consistent production and quality assurance.
Huarun Pharmaceutical (Group) Co., Ltd. (China): As a larger conglomerate, Huarun Pharmaceutical's subsidiaries are involved in API manufacturing, including ephedrine sulfate. Their integrated supply chain and production scale position them as a key supplier.
Jubilant Life Sciences (India): Jubilant is a diversified global pharmaceutical company that manufactures a range of APIs. While specific current production volumes for ephedrine sulfate may vary, their established presence in the API market makes them a notable potential supplier.
Various smaller manufacturers in China and India: Beyond the larger, publicly identified companies, a number of smaller and medium-sized enterprises in these regions also contribute to the ephedrine sulfate supply. These manufacturers often serve regional markets or specific contractual agreements.

Production methodologies vary, with some manufacturers specializing in extraction from Ephedra plants, while others employ complex synthetic chemical processes. The choice of method can influence cost, purity profiles, and environmental impact. Synthetic routes are often favored for their ability to control impurity levels and ensure consistent output, mitigating risks associated with natural source variability and agricultural supply.

What are the key regulatory considerations for Ephedrine Sulfate API production and distribution?

The production and distribution of ephedrine sulfate are subject to stringent international and national regulations due to its potential for diversion into the illicit manufacture of controlled substances, particularly methamphetamine. Regulatory bodies worldwide implement controls to prevent such misuse.

Key regulatory considerations include:

Precursor Chemical Controls: Ephedrine and its salts are classified as List I chemicals by the U.S. Drug Enforcement Administration (DEA) and are similarly controlled under international conventions such as the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. This classification imposes strict record-keeping, reporting, and security requirements on manufacturers, distributors, and importers/exporters.
International Narcotics Control Board (INCB) Oversight: The INCB monitors and controls the international trade of ephedrine and pseudoephedrine, which are precursors for methamphetamine. Countries are obligated to report import and export data to the INCB, which maintains statistics and identifies potential diversion points.
Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines established by regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. GMP ensures that APIs are consistently produced and controlled according to quality standards appropriate for their intended use. This includes rigorous quality control testing, process validation, and documentation.
National Drug Enforcement Agency Regulations: In countries like the United States, the DEA enforces the Controlled Substances Act. Manufacturers and distributors of ephedrine sulfate must register with the DEA, obtain permits for import/export, and maintain detailed transaction records. Sales are often restricted to licensed pharmaceutical manufacturers and distributors.
Import/Export Licensing: Each international transaction involving ephedrine sulfate requires appropriate import and export permits from the relevant authorities in both the exporting and importing countries. These permits ensure that the material is destined for legitimate pharmaceutical use.
Pharmacopoeial Standards: Ephedrine sulfate must meet the purity and quality specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). Compliance with these standards is verified through rigorous analytical testing.
Supply Chain Security: Robust security measures are mandated to prevent theft or diversion of ephedrine sulfate from manufacturing facilities, warehouses, and during transit. This includes physical security, access controls, and background checks for personnel handling the substance.

The regulatory landscape is dynamic, with authorities continually updating controls in response to evolving illicit manufacturing methods and diversion tactics.

What is the current market size and projected growth for Ephedrine Sulfate API?

The market for ephedrine sulfate API is influenced by demand in established therapeutic areas and is subject to the impact of regulatory restrictions on its sale as an over-the-counter (OTC) product in many regions. The primary legitimate uses of ephedrine sulfate are in prescription medications for conditions such as asthma, hypotension associated with anesthesia, and nasal congestion in specific formulations.

Market Size: Estimating the precise current market size for ephedrine sulfate API is challenging due to the proprietary nature of sales data and the consolidation of production among a limited number of suppliers. However, industry reports indicate a global market valued in the tens of millions of U.S. dollars annually. The demand is relatively stable for its approved pharmaceutical applications.
Projected Growth: Projected growth for the ephedrine sulfate API market is modest, estimated to be in the low single digits (e.g., 1-3% CAGR) over the next five to seven years. This growth is primarily driven by:
- Continued Use in Prescription Pharmaceuticals: Its efficacy in treating certain respiratory conditions and acute hypotension ensures ongoing demand from pharmaceutical formulators.
- Emerging Markets: Increased access to healthcare and pharmaceutical manufacturing in developing economies may lead to incremental demand.
- Research and Development: While limited, new therapeutic applications or formulations could theoretically impact demand, though significant growth from R&D is not currently a primary driver.

However, several factors temper growth prospects:

Regulatory Restrictions on OTC Sales: Many countries have banned or severely restricted the sale of ephedrine-containing products OTC due to their potential for abuse and diversion, significantly reducing overall volume demand compared to historical levels.
Availability of Alternatives: The development of alternative bronchodilators and decongestants with better safety profiles or fewer diversion risks has led to a decline in ephedrine sulfate's use in some therapeutic areas.
Stricter Import/Export Controls: The intense regulatory scrutiny and the complexity of international trade compliance can act as a barrier to market expansion for new entrants or smaller players.
Focus on Purity and Safety: Pharmaceutical companies increasingly demand the highest purity APIs, requiring suppliers to invest in advanced manufacturing and quality control, which can influence pricing and production capacity.

The market is characterized by a steady, albeit slow, demand from legitimate pharmaceutical manufacturers, balanced by the significant regulatory hurdles and reduced consumer-level demand.

What are the key challenges and opportunities for Ephedrine Sulfate API suppliers?

Suppliers of ephedrine sulfate API face a complex operating environment shaped by regulatory pressures, supply chain vulnerabilities, and evolving market demands.

Challenges:

Regulatory Compliance Burden: Navigating the intricate web of national and international precursor chemical regulations, import/export controls, and GMP requirements is a significant operational and financial challenge. Failure to comply can result in severe penalties, including fines, license revocation, and criminal prosecution.
Risk of Diversion and Illicit Use: The constant threat of ephedrine sulfate being diverted for illegal methamphetamine production necessitates robust security measures and vigilant monitoring of sales channels. This risk can lead to reputational damage and increased scrutiny from law enforcement.
Supply Chain Volatility: Reliance on specific raw material sources, geopolitical instability in key manufacturing regions, and logistical disruptions can impact production continuity and delivery schedules.
Intense Quality Control Demands: Pharmaceutical clients require APIs to meet exceptionally high purity standards, demanding continuous investment in advanced analytical equipment, process optimization, and skilled personnel.
Competition from Alternatives: The availability of safer, more effective, or less regulated alternative APIs for therapeutic indications previously dominated by ephedrine sulfate puts pressure on market share.
Limited Number of Legitimate Buyers: The restricted legitimate market, primarily comprising established pharmaceutical companies, means suppliers are dependent on a relatively small customer base.

Opportunities:

Niche Therapeutic Demand: For specific, well-established medical applications where ephedrine sulfate remains a preferred or critical treatment option (e.g., anesthesia-induced hypotension, certain severe asthma cases), consistent demand persists. Suppliers meeting stringent quality and regulatory standards can secure long-term contracts.
High-Purity API Specialization: Manufacturers capable of consistently producing ephedrine sulfate API that exceeds pharmacopoeial standards, with minimal impurities, can command premium pricing and attract sophisticated pharmaceutical clients seeking reliable, high-quality inputs.
Contract Manufacturing for Specialized Formulations: Opportunities exist for suppliers to engage in contract manufacturing for pharmaceutical companies developing specialized or complex formulations incorporating ephedrine sulfate, provided they can meet specific client requirements.
Expansion in Emerging Markets (with caution): While regulatory hurdles are present globally, as healthcare infrastructure and regulatory frameworks mature in some emerging economies, there may be opportunities to supply legitimate pharmaceutical manufacturers, provided due diligence is exercised.
Technological Advancement in Synthesis: Investing in and developing more efficient, cost-effective, and environmentally sustainable synthetic routes for ephedrine sulfate can provide a competitive advantage and potentially reduce production costs.
Strategic Partnerships: Forming strategic alliances with pharmaceutical companies or distributors that have established, compliant supply chains can facilitate market access and reduce individual supplier risk.

Suppliers that can effectively manage regulatory complexities, maintain unwavering quality standards, and secure their supply chains are best positioned to thrive in this specialized API market.

Key Takeaways

Global Ephedrine Sulfate API manufacturing is concentrated among a few key suppliers, primarily in China, with India also playing a role.
Stringent regulatory oversight by bodies like the DEA and INCB governs ephedrine sulfate due to its precursor chemical status, imposing strict compliance, security, and reporting requirements.
The API market is characterized by modest growth, driven by its use in specific prescription pharmaceuticals, but tempered by widespread restrictions on OTC sales and the availability of alternatives.
Key challenges for suppliers include navigating complex regulations, mitigating diversion risks, ensuring high-quality production, and facing competition from alternative APIs.
Opportunities lie in serving niche therapeutic demands, specializing in high-purity API production, and exploring strategic partnerships, particularly in regions with maturing regulatory frameworks.

Frequently Asked Questions

1. What is the primary difference between ephedrine and pseudoephedrine concerning their API supply? While both are sympathomimetic amines and can be used as precursors for methamphetamine, ephedrine sulfate is often directly used as a pharmaceutical API for its bronchodilator and vasopressor effects, whereas pseudoephedrine has seen broader use in decongestant formulations, leading to different supply chain management and regulatory focus areas depending on the region and intended application.

2. Are there any new therapeutic applications for ephedrine sulfate currently in development? Current research and development for novel therapeutic applications of ephedrine sulfate are limited. Its established uses are well-defined, and regulatory hurdles associated with its precursor status may disincentivize extensive R&D for new indications compared to other drug classes.

3. How do regulatory changes in one country impact the global supply of Ephedrine Sulfate API? Changes in regulations, particularly concerning precursor chemical controls or import/export restrictions in major manufacturing or consuming countries, can significantly disrupt global supply chains. Increased scrutiny or bans in one jurisdiction can lead to a redirection of supply, increased compliance costs, or even temporary shortages if manufacturers cannot adapt quickly to new requirements.

4. What are the typical quality control tests performed on Ephedrine Sulfate API? Typical quality control tests include identification (using methods like IR spectroscopy), assay (quantifying the ephedrine sulfate content, usually by titration or HPLC), purity tests (detecting related substances, heavy metals, and residual solvents), water content (Karl Fischer titration), and microbial contamination limits, all performed according to pharmacopoeial monographs.

5. What is the typical lead time for sourcing bulk Ephedrine Sulfate API from a certified manufacturer? Lead times can vary significantly based on the supplier's current production schedule, order volume, and existing inventory. However, for certified manufacturers meeting GMP and regulatory requirements, a typical lead time for bulk ephedrine sulfate API can range from 4 to 12 weeks from order confirmation and payment, contingent on necessary import/export permits being secured.

Cited Sources

[1] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - List I and List II Chemicals. Retrieved from [DEA website - specific page on List I chemicals would be linked here if publicly accessible and stable]. [2] International Narcotics Control Board. (n.d.). Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances. United Nations Office on Drugs and Crime. [3] United States Pharmacopeia. (n.d.). United States Pharmacopeia National Formulary (USP-NF). [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). [5] Japanese Pharmacopoeial Society. (n.d.). Japanese Pharmacopoeia (JP).

Suppliers and packagers for EPHEDRINE SULFATE